BIOMAT Database Logo BIOMAT Database Logo

Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. 1999

J N Boletis, and J P Ioannidis, and K A Boki, and H M Moutsopoulos

Among 14 randomised patients with proliferative lupus nephritis, monthly intravenous immunoglobulin maintained remission over 18 months, similar to standard intravenous cyclophosphamide treatment. Pulsed immunoglobulin may be a useful alternative therapy in lupus nephritis.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008181 Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982). Glomerulonephritis, Lupus,Lupus Glomerulonephritis,Nephritis, Lupus,Glomerulonephritides, Lupus,Lupus Glomerulonephritides,Lupus Nephritides,Nephritides, Lupus
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females

Related Publications

J N Boletis, and J P Ioannidis, and K A Boki, and H M Moutsopoulos
Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
January 2005, Lupus,
J N Boletis, and J P Ioannidis, and K A Boki, and H M Moutsopoulos
Intravenous cyclophosphamide in lupus nephritis.
January 1993, Journal of intravenous nursing : the official publication of the Intravenous Nurses Society,
J N Boletis, and J P Ioannidis, and K A Boki, and H M Moutsopoulos
[Intravenous treatment of lupus nephritis with cyclophosphamide].
January 1991, Revista chilena de pediatria,
J N Boletis, and J P Ioannidis, and K A Boki, and H M Moutsopoulos
Intermittent intravenous cyclophosphamide therapy for lupus nephritis.
June 1989, The Journal of pediatrics,
J N Boletis, and J P Ioannidis, and K A Boki, and H M Moutsopoulos
[Assessment on intermittent intravenous cyclophosphamide pulse therapy in diffuse proliferative lupus nephritis].
June 2000, Ryumachi. [Rheumatism],
J N Boletis, and J P Ioannidis, and K A Boki, and H M Moutsopoulos
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
November 2005, The New England journal of medicine,
J N Boletis, and J P Ioannidis, and K A Boki, and H M Moutsopoulos
Intravenous cyclophosphamide for lupus nephritis in Thai children.
January 2004, Scandinavian journal of rheumatology,
J N Boletis, and J P Ioannidis, and K A Boki, and H M Moutsopoulos
Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.
April 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
J N Boletis, and J P Ioannidis, and K A Boki, and H M Moutsopoulos
Intravenous immunoglobulin treatment of lupus nephritis.
April 2000, Seminars in arthritis and rheumatism,
J N Boletis, and J P Ioannidis, and K A Boki, and H M Moutsopoulos
The outcome of proliferative lupus nephritis with pulse cyclophosphamide therapy.
July 2011, Indian journal of nephrology,
Copied contents to your clipboard!